Abstract
The high efficacy of mRNA COVID-19 vaccine encourages the wider application of mRNA therapeutics. Protein replacement therapy with mRNA therapeutics is a promising alternative approach for administering trophic factor proteins in central nervous system disorders or enzyme replacement therapy in inherited enzyme deficient diseases. Although the concept to deliver the mRNA in vivo as a drug was demonstrated as early as 1990, mRNA instability hindered subsequent research development. The polymer-based carrier, polyplex nanomicelle, is a novel carrier for in vivo mRNA administration. Here, we introduce the researches of in vivo mRNA administration using the nanomicelle carrier to treat animal models, especially focusing on the central nervous system disorders including Alzheimer’s disease, spinal cord injury and ischemic brain disease. We discuss the advantages of mRNA therapeutics and the characteristics of diseases which are highly suitable for mRNA therapeutics.
